Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013

Infection

Volumn 45, Issue 2, 2017, Pages 165-170

  Zoufaly, A ^a   Kraft, C ^a   Schmidbauer, C ^a   Puchhammer Stoeckl, E ^b  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

HIV; INSTI; Integrase inhibitor; IRAM; Resistance

Indexed keywords

AMINO ACID; DOLUTEGRAVIR; ELVITEGRAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; AUSTRIAN; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INTEGRASE INHIBITOR RESISTANCE ASSOCIATED MUTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; VIROLOGY; VIRUS RESISTANCE; YOUNG ADULT; ANTIVIRAL RESISTANCE; AUSTRIA; CROSS-SECTIONAL STUDY; GENETICS; MISSENSE MUTATION; RETROSPECTIVE STUDY;

ADULT; AUSTRIA; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HUMANS; INTEGRASE INHIBITORS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREVALENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84982128199     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-016-0936-5     Document Type: Article

References (24)

1. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796–806. doi:10.1016/S0140-6736(09)60918-1.
2. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439–48. doi:10.1016/S0140-6736(12)60917-9.
3. Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS. 2014;28:813–9. doi:10.1097/QAD.0000000000000199.
4. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52:1351–8. doi:10.1128/AAC.01228-07.
5. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–65. doi:10.1056/NEJMoa0708978.
6. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82:10366–74. doi:10.1128/JVI.00470-08.
7. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63:77–85. doi:10.1097/QAI.0b013e31828ace69.
8. Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013;13:587–96. doi:10.1016/S1473-3099(13)70093-8.
9. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2015;. doi:10.1093/cid/civ963.
10. Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007–2013. Antivir Ther. 2015;20:77–80. doi:10.3851/IMP2780.
11. Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, et al. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naive and pretreated patients. Clin Microbiol Infect. 2012;18:E428–30. doi:10.1111/j.1469-0691.2012.03917.x.
12. Gutierrez C, Hernandez-Novoa B, Perez-Elias MJ, Moreno AM, Holguin A, Dronda F, et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials. 2013;14:10–6. doi:10.1410/hct1401-10.
13. Sichtig N, Sierra S, Kaiser R, Daumer M, Reuter S, Schulter E, et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother. 2009;64:25–32. doi:10.1093/jac/dkp153.
14. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608–18. doi:10.1086/503914.
15. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 2015 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2015;23:132–41.
16. Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008;80:213–22. doi:10.1016/j.antiviral.2008.06.012.
17. (AHIVCOS) AHCS. HIV/AIDS in Austria: 26th report of the Austrian HIV cohort study. Innsbruck: STUDIA Universitätsverlag; 2014.
18. DAIG. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. 2012. http://www.daignet.de/site-content/hiv-therapie/leitlinien-1/Anlage%201%20LL%20055-001%20Version%206%2011-12-2015%20endgultige%20Version%20rev-2.pdf. Accessed 12 Aug 2016.
19. Souza Cavalcanti J, Minhoto Lanca A, de Paula Ferreira JL, da Eira M, de Souza Dantas DS, de Macedo Brigido LF. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen. Antiviral Res. 2012;95:9–11. doi:10.1016/j.antiviral.2012.04.007.
20. Munir S, Thierry E, Malet I, Subra F, Calvez V, Marcelin AG, et al. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemother. 2015;70:739–49. doi:10.1093/jac/dku474.
21. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis. 2013;208:1102–12. doi:10.1093/infdis/jit310.
22. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483–9.
23. Casadella M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, et al. Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother. 2015;70:2885–8. doi:10.1093/jac/dkv202.
24. Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA, et al. Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom. Clin Infect Dis. 2015;61:829–36. doi:10.1093/cid/civ393.